The European and Developing Countries Clinical Trials Partnership (EDCTP) was created in 2003 as a European response to the global health crisis of poverty-related diseases. It is a public-public partnership between countries in Europe, and in sub-Saharan Africa, as well as the European Commission.
The objective is to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials.
The second EDCTP programme (EDCTP2, 2014-2024) was launched in December 2014. It is co-funded by the European Union via Horizon 2020. The EU will provide a contribution of up to € 683 million for the 10-year programme, provided this is matched by contributions from the European Partipating States. The EDCTP2 programme is implemented by the EDCTP Association which currently counts 28 countries as full and equal members: 14 African and 14 European countries:
- Burkina Faso, Cameroon, Congo, Gabon, The Gambia, Ghana, Mali, Mozambique, Niger, Senegal, South Africa, Tanzania, Uganda, and Zambia
- Austria, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden, and the United Kingdom
EDCTP2 makes the European Union a stronger global player in health research and complements other initiatives with third countries, for example the Global Research Collaboration for Infectious Diseases (GloPID-R), a multi-funder initiative of 23 members and the World Health Organization, with funders from Australia, Brazil, Canada, France, Korea, South Africa, Spain, Thailand and the US. GloPID-R is a network of funders to facilitate an effective research response within 48 hours of a significant outbreak of a new or re-emerging infectious disease with pandemic potential, in order to save lives and economies worldwide.